Notice of Full Year 2021 Results and Investor Presentation

Paris, France and Camberley, UK – 20 April 2022 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it will report its audited financial results for the year ended 31 December 2021 on Thursday, 28 April 2022. http://novacyt.com/wp-content/uploads/2022/04/Notice-of-FY21-Results-.pdf

Visit Page

Approval of second direct-to-PCR COVID-19 test in the UK under CTDA legislation

Paris, France and Camberley, UK – 12 April 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s PROmate® COVID-19 1G (q32) Real-Time PCR test has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”).

Visit Page

Director/PDMR Shareholding

Paris, France and Camberley, UK – 25 March 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 25 March 2022, the following Director purchased ordinary shares of €1/15 each in the Company (the “Ordinary Shares”): http://novacyt.com/wp-content/uploads/2022/03/3.-Novacyt-Director-Dealings-DA-ENG.pdf

Visit Page